Asthma Management Guidelines

Introduction to Asthma Management

• Asthma diagnosis should be confirmed through clinical history, family history, and objective testing with spirometry showing bronchodilator reversibility, and peak expiratory flow (PEF) monitoring in pediatric patients with suspected asthma, as recommended by the American Thoracic Society and supported by the Global Initiative for Asthma (GINA) 1, 2, 3
• The diagnosis of asthma is based on episodes of acute or subacute worsening in symptoms and lung function, according to GINA 2

First-Line and Add-On Therapies

• Daily low-dose inhaled corticosteroids (ICS) + as-needed short-acting beta-agonists (SABA) are recommended as the preferred treatment for pediatric patients with asthma, with consideration of leukotriene receptor antagonist (LTRA) for children unable to use ICS, as recommended by the American Academy of Allergy, Asthma, and Immunology and supported by the American Academy of Pediatrics 4, 5
• For moderate-severe persistent asthma, combination therapy with ICS + LABA is preferred, as recommended by the American Academy of Allergy, Asthma, and Immunology 6

• Age-specific treatment options include:

  Age	Preferred Treatment
  <5 years	Budesonide nebulizer solution
  ≥5 years	Fluticasone DPI
  ≥4 years	Salmeterol DPI for inadequate control

• Inhaled corticosteroids, such as fluticasone DPI 100-200 mcg/day, are recommended for children ≥5 years with mild to moderate persistent asthma, with the option to increase to medium dose (up to 500 mcg/day) or add a long-acting beta2-agonist for inadequate control, according to the American Academy of Family Physicians 8
• Subcutaneous allergen immunotherapy (SCIT) can be considered for allergic asthma, as recommended by 5

Medication Approval and Safety

• The FDA has approved certain medications for children 5-11 years old, including ICS + LABA combinations, with the caveat that Symbicort is only approved for patients ≥12 years of age in the United States, highlighting the need for age-appropriate treatment options 9
• The American Thoracic Society, as reflected in the EPR-3 guidelines, recommends for children 5-11 years old, the use of ICS + LABA combinations approved for this age group for moderate-severe persistent asthma, with options including increasing to medium-dose ICS or adding a leukotriene receptor antagonist (LTRA) for inadequate control 9
• The EPR-3 guidelines emphasize that LABAs should not be used as monotherapy due to safety concerns, particularly in younger children 7

Asthma Exacerbation Management

• Severe exacerbation signs include being too breathless to talk or feed, respiratory rate >50 breaths/min, heart rate >140 beats/min, and PEF <50% predicted, as defined by the British Thoracic Society 1
• Life-threatening features of asthma exacerbation include PEF <33% predicted, cyanosis, silent chest, fatigue or exhaustion, and reduced consciousness, as identified by the British Thoracic Society 1
• The British Thoracic Society recommends administering high-flow oxygen to maintain SaO₂ >92%, frequent short-acting β-agonist via oxygen-driven nebulizer, and systemic corticosteroids, with consideration of adding ipratropium bromide, for the management of severe asthma exacerbations 1
• Oxygen supplementation with a target saturation of 92-95% is recommended, along with frequent SABA use, systemic corticosteroids, and ipratropium bromide in combination with SABA to manage acute exacerbations, as supported by 2
• For moderate to severe exacerbations, systemic corticosteroids should be considered, with a recommended dosage of 1-2 mg/kg/day 1, 10

Prevention and Education

• Annual influenza vaccination is recommended for all asthmatic children >6 months, with a vaccine efficacy of 80% 9
• Multicomponent allergen-specific mitigation and avoidance of tobacco smoke exposure can help prevent asthma exacerbations, with a relative risk reduction of 50% 9
• Proper inhaler technique, differentiation between reliever and controller medications, and a written asthma action plan are essential for effective asthma management, as recommended by the EPR-3 guidelines and supported by 9, 1
• Parents and patients should be educated on proper inhaler technique and the use of a peak flow meter (when age-appropriate), the difference between "relievers" (bronchodilators) and "preventers" (anti-inflammatory treatments), recognition of worsening symptoms, and when to seek urgent medical attention, according to the guidelines from the Thorax journal 1

Follow-Up and Monitoring

• Follow-up should be scheduled within 1-4 weeks after treatment changes, with monitoring of frequency of SABA use and assessment of inhaler technique at every visit, as recommended by the American Thoracic Society and supported by the American Academy of Pediatrics 1, 5
• Assessing inhaler technique at every visit and addressing environmental triggers can help optimize asthma management, as recommended by the American Academy of Pediatrics and supported by 5
• Asthma control in children is categorized into three levels: well-controlled, not well-controlled, and very poorly controlled, based on symptoms, nighttime awakenings, activity limitations, and rescue medication use, with specific criteria for each level, including symptoms ≤2 days/week, nighttime awakenings ≤1 time/month, and short-acting β2-agonist use ≤2 days/week for well-controlled asthma, as recommended by the American Academy of Pediatrics 7
• Hospital admission indicators for infants include oxygen saturation <92% or cyanosis, respiratory rate >70 breaths/min, difficulty breathing or grunting, intermittent apnea, not feeding, and family unable to provide appropriate supervision, while for older children, indicators include oxygen saturation <92% or cyanosis, respiratory rate >50 breaths/min, difficulty breathing or grunting, signs of dehydration, and family unable to provide appropriate supervision, as supported by 11
• Referral to an asthma specialist is recommended when difficulties achieving or maintaining control, recurrent exacerbations despite appropriate therapy, or considering biologics like omalizumab, with a referral rate of 20% 9